Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 84.25% |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -10.84% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 26.38% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 34.98% |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -46.86% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 13.80% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | -3.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.00% |
| Dec 31, 2025 | 65.60% |
| Sep 30, 2025 | 15.03% |
| Jun 30, 2025 | -41.77% |
| Mar 31, 2025 | 5.28% |
| Dec 31, 2024 | 51.23% |
| Sep 30, 2024 | 27.37% |
| Jun 30, 2024 | -5.15% |
| Mar 31, 2024 | -65.45% |
| Dec 31, 2023 | -89.37% |
| Sep 30, 2023 | 3.44% |
| Jun 30, 2023 | 7.29% |
| Mar 31, 2023 | 19.45% |
| Dec 31, 2022 | -39.83% |
| Sep 30, 2022 | 32.96% |
| Jun 30, 2022 | 40.70% |
| Mar 31, 2022 | -30.69% |
| Dec 31, 2021 | 14.83% |
| Sep 30, 2021 | -28.42% |
| Jun 30, 2021 | -2.24% |